CN101487062B - 同步检测肝炎、艾滋病毒和梅毒螺旋体核酸的试剂盒 - Google Patents
同步检测肝炎、艾滋病毒和梅毒螺旋体核酸的试剂盒 Download PDFInfo
- Publication number
- CN101487062B CN101487062B CN2008101974852A CN200810197485A CN101487062B CN 101487062 B CN101487062 B CN 101487062B CN 2008101974852 A CN2008101974852 A CN 2008101974852A CN 200810197485 A CN200810197485 A CN 200810197485A CN 101487062 B CN101487062 B CN 101487062B
- Authority
- CN
- China
- Prior art keywords
- virus
- hepatitis
- aids
- sequence
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 34
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 33
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 32
- 208000006454 hepatitis Diseases 0.000 title claims abstract description 12
- 231100000283 hepatitis Toxicity 0.000 title claims abstract description 12
- 208000006379 syphilis Diseases 0.000 title claims description 22
- 241000725303 Human immunodeficiency virus Species 0.000 title abstract description 20
- 239000003153 chemical reaction reagent Substances 0.000 title description 10
- 241000589884 Treponema pallidum Species 0.000 claims abstract description 32
- 102000004190 Enzymes Human genes 0.000 claims abstract description 30
- 108090000790 Enzymes Proteins 0.000 claims abstract description 30
- 241000700721 Hepatitis B virus Species 0.000 claims abstract description 24
- 241000711549 Hepacivirus C Species 0.000 claims abstract description 22
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 16
- 238000000605 extraction Methods 0.000 claims abstract description 14
- 244000052769 pathogen Species 0.000 claims abstract description 12
- 239000007788 liquid Substances 0.000 claims abstract description 11
- 239000013612 plasmid Substances 0.000 claims abstract description 11
- 208000030507 AIDS Diseases 0.000 claims description 48
- 241000700605 Viruses Species 0.000 claims description 47
- 238000001514 detection method Methods 0.000 claims description 47
- 230000001717 pathogenic effect Effects 0.000 claims description 36
- 238000012360 testing method Methods 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 28
- 239000003795 chemical substances by application Substances 0.000 claims description 25
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 21
- 239000012634 fragment Substances 0.000 claims description 20
- 239000002773 nucleotide Substances 0.000 claims description 19
- 125000003729 nucleotide group Chemical group 0.000 claims description 19
- 208000005176 Hepatitis C Diseases 0.000 claims description 13
- 239000007850 fluorescent dye Substances 0.000 claims description 13
- 230000002441 reversible effect Effects 0.000 claims description 8
- 108700004026 gag Genes Proteins 0.000 claims description 6
- 101150098622 gag gene Proteins 0.000 claims description 6
- 208000002672 hepatitis B Diseases 0.000 claims description 6
- 238000010791 quenching Methods 0.000 claims description 6
- 230000000171 quenching effect Effects 0.000 claims description 6
- 241000894006 Bacteria Species 0.000 claims description 5
- 230000000968 intestinal effect Effects 0.000 claims description 5
- 238000012408 PCR amplification Methods 0.000 claims description 4
- 239000012154 double-distilled water Substances 0.000 claims description 4
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 claims description 4
- 229920002527 Glycogen Polymers 0.000 claims description 3
- 108091026898 Leader sequence (mRNA) Proteins 0.000 claims description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical group OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims description 3
- 229940096919 glycogen Drugs 0.000 claims description 3
- 239000001509 sodium citrate Substances 0.000 claims description 3
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 claims description 3
- 229940038773 trisodium citrate Drugs 0.000 claims description 3
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 claims description 3
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 39
- 239000008280 blood Substances 0.000 abstract description 39
- 238000003745 diagnosis Methods 0.000 abstract description 9
- 238000012216 screening Methods 0.000 abstract description 7
- 230000008901 benefit Effects 0.000 abstract description 6
- 230000035945 sensitivity Effects 0.000 abstract description 6
- 239000002253 acid Substances 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 description 49
- 239000000523 sample Substances 0.000 description 49
- 230000001360 synchronised effect Effects 0.000 description 17
- 239000000047 product Substances 0.000 description 16
- 238000003753 real-time PCR Methods 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 239000010836 blood and blood product Substances 0.000 description 9
- 229940125691 blood product Drugs 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 208000035473 Communicable disease Diseases 0.000 description 7
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 7
- 210000002381 plasma Anatomy 0.000 description 7
- 108091008146 restriction endonucleases Proteins 0.000 description 7
- 230000003321 amplification Effects 0.000 description 6
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 238000003199 nucleic acid amplification method Methods 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000013207 serial dilution Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 5
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 5
- 238000011529 RT qPCR Methods 0.000 description 5
- 230000004087 circulation Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000010839 reverse transcription Methods 0.000 description 5
- 108010042407 Endonucleases Proteins 0.000 description 4
- 102000004533 Endonucleases Human genes 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 230000002103 transcriptional effect Effects 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 238000009004 PCR Kit Methods 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 238000012790 confirmation Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000001915 proofreading effect Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 125000006853 reporter group Chemical group 0.000 description 3
- 101100275473 Caenorhabditis elegans ctc-3 gene Proteins 0.000 description 2
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 2
- 208000006154 Chronic hepatitis C Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000008118 PEG 6000 Substances 0.000 description 2
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 2
- 241000589970 Spirochaetales Species 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 208000010710 hepatitis C virus infection Diseases 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 238000001216 nucleic acid method Methods 0.000 description 2
- 230000001902 propagating effect Effects 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- SNBCLPGEMZEWLU-QXFUBDJGSA-N 2-chloro-n-[[(2r,3s,5r)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl]acetamide Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CNC(=O)CCl)[C@@H](O)C1 SNBCLPGEMZEWLU-QXFUBDJGSA-N 0.000 description 1
- 102100038108 Arylamine N-acetyltransferase 1 Human genes 0.000 description 1
- 101710124345 Arylamine N-acetyltransferase 1 Proteins 0.000 description 1
- 101100268670 Caenorhabditis elegans acc-3 gene Proteins 0.000 description 1
- 101100004280 Caenorhabditis elegans best-2 gene Proteins 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000005189 flocculation Methods 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 238000011194 good manufacturing practice Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 210000004914 menses Anatomy 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 208000002040 neurosyphilis Diseases 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 101150055096 polA gene Proteins 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000012913 prioritisation Methods 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000005758 transcription activity Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Images
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008101974852A CN101487062B (zh) | 2008-10-31 | 2008-10-31 | 同步检测肝炎、艾滋病毒和梅毒螺旋体核酸的试剂盒 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008101974852A CN101487062B (zh) | 2008-10-31 | 2008-10-31 | 同步检测肝炎、艾滋病毒和梅毒螺旋体核酸的试剂盒 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101487062A CN101487062A (zh) | 2009-07-22 |
CN101487062B true CN101487062B (zh) | 2013-11-27 |
Family
ID=40890122
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2008101974852A Active CN101487062B (zh) | 2008-10-31 | 2008-10-31 | 同步检测肝炎、艾滋病毒和梅毒螺旋体核酸的试剂盒 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101487062B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107287348A (zh) * | 2017-06-19 | 2017-10-24 | 广州和实生物技术有限公司 | 一种血筛三项多色单管检测试剂盒 |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101886140B (zh) * | 2010-07-06 | 2012-09-05 | 上海市血液中心 | 针对病毒性肝炎病原体的多重pcr检测试剂盒及其制备和应用 |
CN102277418A (zh) * | 2011-01-26 | 2011-12-14 | 宁波基内生物技术有限公司 | 一种用于检测梅毒螺旋体的引物、试剂盒及方法 |
CN102212618B (zh) * | 2011-05-22 | 2013-02-27 | 浙江大学 | 四重荧光定量pcr检测试剂盒及用途 |
CN102634453A (zh) * | 2012-05-08 | 2012-08-15 | 厦门大学附属中山医院 | 梅毒螺旋体bmp基因FQ-PCR检测试剂盒及其制备 |
CN102634452A (zh) * | 2012-05-08 | 2012-08-15 | 厦门大学附属中山医院 | 梅毒螺旋体tpn47基因fq-pcr检测试剂盒及其制备 |
CN102634451A (zh) * | 2012-05-08 | 2012-08-15 | 厦门大学附属中山医院 | 梅毒螺旋体fla-A基因FQ-PCR检测试剂盒及其制备 |
US20170044631A1 (en) * | 2014-04-14 | 2017-02-16 | The Unite States of America, as represented by the Secretary, Dept. of Health and Human Services | Methods for rapid detection and identification of viral nucleic acids |
JP6685138B2 (ja) * | 2016-01-27 | 2020-04-22 | シスメックス株式会社 | 核酸増幅の精度管理方法、精度管理用試薬およびその試薬キット |
CN105624311A (zh) * | 2016-03-08 | 2016-06-01 | 湖南圣湘生物科技有限公司 | 单管中多重靶核酸的实时荧光pcr检测方法及其试剂盒 |
CN106834542B (zh) * | 2017-02-17 | 2020-04-14 | 东莞市儿童医院 | 一种同步扩增检测hcmv、hsv1、hsv2和b19的引物、探针、试剂盒及方法 |
CN109777891A (zh) * | 2019-03-19 | 2019-05-21 | 上海邦耀生物科技有限公司 | 一种检测gag基因的引物对和荧光探针的组合和检测方法 |
CN114375342A (zh) * | 2019-07-30 | 2022-04-19 | 东洋纺株式会社 | 经改良的病毒检测方法 |
CN111206116A (zh) * | 2019-11-19 | 2020-05-29 | 武汉尚码生物科技有限公司 | 一种人四种传染病的快速检测方法、液相芯片及试剂盒 |
CN113234866B (zh) * | 2021-06-30 | 2023-11-14 | 上海君远生物科技有限公司 | 一种同步检测多项血液循环系统病原体的检测试剂盒及其检测方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1346893A (zh) * | 2001-09-30 | 2002-05-01 | 武汉大学 | 以Taq酶对DNA和RNA病原进行同步PCR检测的方法 |
CN1405322A (zh) * | 2001-08-09 | 2003-03-26 | 上海博华基因芯片技术有限公司 | 一种对丙肝、乙肝、爱滋和梅毒病毒进行共检的基因芯片及其检测方法 |
CN1405564A (zh) * | 2001-08-17 | 2003-03-26 | 上海数康生物科技有限公司 | 用于同时检测多种传染性疾病的试剂盒及其制备方法 |
CN1940087A (zh) * | 2006-08-18 | 2007-04-04 | 上海科华生物工程股份有限公司 | 一种同步扩增检测肝炎及艾滋病毒核酸的方法及试剂盒 |
-
2008
- 2008-10-31 CN CN2008101974852A patent/CN101487062B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1405322A (zh) * | 2001-08-09 | 2003-03-26 | 上海博华基因芯片技术有限公司 | 一种对丙肝、乙肝、爱滋和梅毒病毒进行共检的基因芯片及其检测方法 |
CN1405564A (zh) * | 2001-08-17 | 2003-03-26 | 上海数康生物科技有限公司 | 用于同时检测多种传染性疾病的试剂盒及其制备方法 |
CN1346893A (zh) * | 2001-09-30 | 2002-05-01 | 武汉大学 | 以Taq酶对DNA和RNA病原进行同步PCR检测的方法 |
CN1940087A (zh) * | 2006-08-18 | 2007-04-04 | 上海科华生物工程股份有限公司 | 一种同步扩增检测肝炎及艾滋病毒核酸的方法及试剂盒 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107287348A (zh) * | 2017-06-19 | 2017-10-24 | 广州和实生物技术有限公司 | 一种血筛三项多色单管检测试剂盒 |
Also Published As
Publication number | Publication date |
---|---|
CN101487062A (zh) | 2009-07-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101487062B (zh) | 同步检测肝炎、艾滋病毒和梅毒螺旋体核酸的试剂盒 | |
Afzal et al. | Absence of detectable measles virus genome sequence in blood of autistic children who have had their MMR vaccination during the routine childhood immunization schedule of UK | |
CN109609689B (zh) | 用于检测肠道病毒的核酸试剂、试剂盒及系统 | |
CN101886138A (zh) | 肠道病毒71型、柯萨奇病毒a16型和肠道病毒其它各亚型三色荧光rt-pcr联合检测方法及其试剂盒 | |
WO2018035860A1 (zh) | 同时检测及定量分析四种血源性病毒的多重Taqman探针qPCR的试剂盒及方法 | |
CN101017140A (zh) | 人肠道病毒(ev)荧光定量pcr检测技术 | |
CN102559930A (zh) | 一种荧光定量rt-pcr检测丙型肝炎病毒的试剂盒 | |
CN109576397A (zh) | 一种人类免疫缺陷病毒1型核酸定量检测试剂盒 | |
Saad et al. | Prevalence of occult hepatitis C in Egyptian patients with non alcoholic fatty liver disease | |
CN107529559A (zh) | 一种手足口病病毒的多重荧光pcr检测试剂盒、及应用 | |
CN109439777A (zh) | 梅毒螺旋体(tp)-pcr荧光检测试剂盒 | |
CN101871013B (zh) | 检测水痘-带状疱疹病毒的试剂盒 | |
CN103045756A (zh) | 一种荧光定量rt-pcr检测人类免疫缺陷病毒1型的试剂盒 | |
CN103966356A (zh) | 人类免疫缺陷病毒1型一步法荧光定量pcr检测试剂盒 | |
CN104846116B (zh) | 检测人类免疫缺陷病毒1型的pcr引物组、探针及其试剂盒和检测方法 | |
CN102719566A (zh) | 检测牛流行热病毒的核苷酸序列和试剂盒 | |
Jongen et al. | Polymyositis and dermatomyositis: no persistence of enterovirus or encephalomyocarditis virus RNA in muscle. | |
CN102108420B (zh) | 一种检测登革1型病毒的荧光定量pcr试剂盒 | |
CN109321683A (zh) | 一种a型塞尼卡病毒检测引物、试剂盒、病毒检测方法和应用 | |
CN114085929A (zh) | 一种用于检测非洲猪瘟病毒野毒株和疫苗株的试剂盒 | |
Ikomey et al. | Observed HIV drug resistance associated mutations amongst naïve immunocompetent children in Yaoundé, Cameroon | |
CN103131797A (zh) | 一种博卡病毒实时荧光pcr检测试剂盒及其应用 | |
US20100255459A1 (en) | Control for virus detection assays based on reverse-transcription polymerase chain reaction | |
Hazazi et al. | Hepatitis C Virus Genotyping in Saudi Population | |
US20160289778A1 (en) | Hcv genotyping algorithm |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: WUHAN ZHENFU PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: WUHAN UNIVERSITY Effective date: 20140729 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 430072 WUHAN, HUBEI PROVINCE TO: 430074 WUHAN, HUBEI PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20140729 Address after: 430074 No. 166, hi tech Avenue, East Lake Development Zone, Hubei, Wuhan Patentee after: WUHAN ZHENFU PHARMACEUTICAL Co.,Ltd. Address before: 430072 Hubei city of Wuhan province Wuchang Luojiashan Patentee before: Wuhan University |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240108 Address after: Buildings 1, 2, and 4, Phase I of Donghu High tech Smart City, No. 216 Jianshe Avenue, Gedian Development Zone, Ezhou City, Hubei Province, 436070 Patentee after: Hubei Zhen Fu Pharmaceutical Co.,Ltd. Address before: No. 166 Gaoxin Avenue, Donghu Development Zone, Wuhan, Hubei Province, 430074 Patentee before: WUHAN ZHENFU PHARMACEUTICAL Co.,Ltd. |